Mehitazin

С Википедије, слободне енциклопедије
Mehitazin
Klinički podaci
Prodajno imeButix, Instotal, Kitazemin, Metaplexan
Drugs.comMonografija
Identifikatori
CAS broj29216-28-2 ДаY
ATC kodR06AD07 (WHO)
PubChemCID 4066
DrugBankDB01071 ДаY
ChemSpider3926 ДаY
KEGGC12755 ДаY
Hemijski podaci
FormulaC20H22N2S
Molarna masa322,467
  • C(C1CN2CCC1CC2)N1C2=CC=CC=C2SC2=CC=CC=C12
  • InChI=1S/C20H22N2S/c1-3-7-19-17(5-1)22(18-6-2-4-8-20(18)23-19)14-16-13-21-11-9-15(16)10-12-21/h1-8,15-16H,9-14H2 ДаY
  • Key:HOKDBMAJZXIPGC-UHFFFAOYSA-N ДаY
Fizički podaci
Tačka topljenja1.305 °C (2.381 °F)

Mehitazin je organsko jedinjenje, koje sadrži 20 atoma ugljenika i ima molekulsku masu od 322,467 Da.[1][2][3][4][5][6]

Osobine[уреди | уреди извор]

Osobina Vrednost
Broj akceptora vodonika 3
Broj donora vodonika 0
Broj rotacionih veza 2
Particioni koeficijent[7] (ALogP) 4,4
Rastvorljivost[8] (logS, log(mol/L)) -4,4
Polarna površina[9] (PSA, Å2) 31,8

Reference[уреди | уреди извор]

  1. ^ Ramirez Chanona N, del Rio Navarro BE, Perez Martin J: [Efficacy of mequitazine (Primalan) on the relief of symptoms of allergic rhinoconjunctivitis in children. Documented clinical experience] Rev Alerg Mex. 2005 Nov-Dec;52(6):221-5. PMID 16568706
  2. ^ Theunissen EL, Vermeeren A, van Oers AC, van Maris I, Ramaekers JG: A dose-ranging study of the effects of mequitazine on actual driving, memory and psychomotor performance as compared to dexchlorpheniramine, cetirizine and placebo. Clin Exp Allergy. 2004 Feb;34(2):250-8. PMID 14987305
  3. ^ Nakamura K, Yokoi T, Kodama T, Inoue K, Nagashima K, Shimada N, Shimizu T, Kamataki T: Oxidation of histamine H1 antagonist mequitazine is catalyzed by cytochrome P450 2D6 in human liver microsomes. J Pharmacol Exp Ther. 1998 Feb;284(2):437-42. PMID 9454781
  4. ^ Persi L, Dupin O, Arnaud B, Trinquand C, Michel FB, Bousquet J: Efficacy of mequitazine in comparison with placebo assessed by ocular challenge with allergen in allergic conjunctivitis. Allergy. 1997 Apr;52(4):451-4. PMID 9188930
  5. ^ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035—41. PMC 3013709Слободан приступ. PMID 21059682. doi:10.1093/nar/gkq1126.  уреди
  6. ^ David S. Wishart; Craig Knox; An Chi Guo; Dean Cheng; Savita Shrivastava; Dan Tzur; Bijaya Gautam; Murtaza Hassanali (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic acids research. 36 (Database issue): D901—6. PMC 2238889Слободан приступ. PMID 18048412. doi:10.1093/nar/gkm958.  уреди
  7. ^ Ghose, A.K.; Viswanadhan V.N. & Wendoloski, J.J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragment Methods: An Analysis of AlogP and CLogP Methods”. J. Phys. Chem. A. 102: 3762—3772. doi:10.1021/jp980230o. 
  8. ^ Tetko IV, Tanchuk VY, Kasheva TN, Villa AE (2001). „Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices”. Chem Inf. Comput. Sci. 41: 1488—1493. PMID 11749573. doi:10.1021/ci000392t.  уреди
  9. ^ Ertl P.; Rohde B.; Selzer P. (2000). „Fast calculation of molecular polar surface area as a sum of fragment based contributions and its application to the prediction of drug transport properties”. J. Med. Chem. 43: 3714—3717. PMID 11020286. doi:10.1021/jm000942e.  уреди

Literatura[уреди | уреди извор]

Spoljašnje veze[уреди | уреди извор]


Molimo Vas, obratite pažnju na važno upozorenje
u vezi sa temama iz oblasti medicine (zdravlja).